Search results
Results from the WOW.Com Content Network
Since alpha-glucosidase inhibitors prevent the degradation of complex carbohydrates into glucose, the carbohydrates will remain in the intestine. In the colon, bacteria will digest the complex carbohydrates, thereby causing gastrointestinal side effects such as flatulence and diarrhea. Since these effects are dose-related, it is generally ...
Acarbose degradation is the unique feature of glycoside hydrolases in gut microbiota, acarbose degrading glucosidase, which hydrolyze acarbose into an acarviosine-glucose and glucose. [17] Human enzymes do transform acarbose: the pancreatic alpha-amylase is able to perform a rearrangement reaction , moving the glucose unit in the "tail" maltose ...
Alpha-glucosidase inhibitors are a class of diabetes drugs found in plants/herbs like cinnamon; [3] however, they are technically not hypoglycemic agents because they do not have a direct effect on insulin secretion or sensitivity. These agents slow the digestion of starch in the small intestine, such that glucose from the starch enters the ...
Miglitol is an oral alpha-glucosidase inhibitor used in the treatment of type 2 diabetes.It works by reversibly inhibiting alpha-glucosidase enzymes in the small intestine, which delays the digestion of complex carbohydrates and subsequently reduces postprandial glucose levels. [1]
ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Chemically, the drug is an analog of the enzyme that is deficient in patients affected by Pompe disease, alpha-glucosidase. It is the first drug available to treat this disease. [2] It was approved for medical use in the United States in April 2006, as Myozyme [7] and in May 2010, as Lumizyme. [8]
Common side effects include nausea and heartburn. [1] Serious side effects may include angioedema and low blood sugar. [1] It is generally not recommended during pregnancy but can be used during breastfeeding. [3] It is in the sulfonylureas class of medications and works by increasing the release of insulin from the pancreas. [1]
Side effects include weight gain and hypoglycemia. While the potential for hypoglycemia is less than for those on sulfonylureas, [citation needed] it is still a serious potential side effect that can be life-threatening. Patients on this medication should know the signs and symptoms of hypoglycemia and appropriate management.